A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis

被引:169
作者
Popat, S [1 ]
Houlston, RS
机构
[1] Royal Marsden Hosp, Dept Med, London SW3 6JJ, England
[2] Inst Canc Res, Sect Canc Genet, Sutton SM2 5NG, Surrey, England
关键词
allelic imbalance; chromosome; 18q; colorectal cancer; DCC; meta-analysis;
D O I
10.1016/j.ejca.2005.04.039
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Results from studies investigating the relationship between colorectal cancer survival and chromosome 18q allelic imbalance (AI)/ loss of DCC expression (LOE) have been inconsistent. We have reviewed and pooled published studies to estimate the prognostic significance of chromosome 18q status more precisely. Data from 27 studies were eligible. Survival data were pooled using standard meta-analysis techniques. Considerable variation between assessment method, marker choice, and threshold for assigning AI/LOE was observed. Pooling data from a 2189 cases from 17 studies showed significantly worse overall survival in patients with AI/LOE (HR = 2.00, 95%CI: 1.49-2.69), maintained both in the adjuvant setting (HR = 1.69, 95%CI: 1. 13-2.54), and also by method (FIR = 1.67, 95%CI: 1. 19-2.36, genotyping microsatellites; HR = 3.00, 95%CI: 1.98-4.56, immunohistochemistry). There was however evidence of heterogeneity and publication bias. Cancers with chromosome 18q loss appear to have a poorer prognosis. Prospective studies using consistent methodology are needed to precisely quantify its effect and role in patients with stage II-III disease. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2060 / 2070
页数:11
相关论文
共 65 条
[1]
Alderson P., 2004, COCHRANE REV HDB 4 2
[2]
[Anonymous], CANC FACTS FIG 2004
[3]
Deleted in colon cancer protein expression in colorectal cancer metastases: A major predictor of survival in patients with unresectable metastatic disease receiving palliative fluorouracil-based chemotherapy [J].
Aschele, C ;
Debernardis, D ;
Lonardi, S ;
Bandelloni, R ;
Casazza, S ;
Monfardini, S ;
Gallo, L .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (18) :3758-3765
[4]
BARDI G, 1993, CANCER, V71, P306, DOI 10.1002/1097-0142(19930115)71:2<306::AID-CNCR2820710207>3.0.CO
[5]
2-C
[6]
Tumor karyotype predicts clinical outcome in colorectal cancer patients [J].
Bardi, G ;
Fenger, C ;
Johansson, B ;
Mitelman, F ;
Heim, S .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (13) :2623-2634
[7]
DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: a molecular study [J].
Barratt, PL ;
Seymour, MT ;
Stenning, SP ;
Georgiades, I ;
Walker, C ;
Birbeck, K ;
Quirke, P .
LANCET, 2002, 360 (9343) :1381-1391
[8]
OPERATING CHARACTERISTICS OF A BANK CORRELATION TEST FOR PUBLICATION BIAS [J].
BEGG, CB ;
MAZUMDAR, M .
BIOMETRICS, 1994, 50 (04) :1088-1101
[9]
Bendardaf R, 2004, ANTICANCER RES, V24, P2519
[10]
American society of clinical oncology recommendations on adjuvant chemotherapy for stage II colon cancer [J].
Benson, AB ;
Schrag, D ;
Somerfield, MR ;
Cohen, AM ;
Figueredo, AT ;
Flynn, PJ ;
Krzyzanowska, MK ;
Maroun, J ;
McAllister, P ;
Van Cutsem, E ;
Brouwers, M ;
Charette, M ;
Haller, DG .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (16) :3408-3419